AAAAAA

   
Results: 1-17 |
Results: 17
BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer
Authors: Schoumacher, F Glaus, A Mueller, H Eppenberger, U Bolliger, B Senn, HJ
Citation: F. Schoumacher et al., BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer, SWISS MED W, 131(15-16), 2001, pp. 223-226
A cordial greeting
Authors: Senn, HJ
Citation: Hj. Senn, A cordial greeting, BREAST, 10(5), 2001, pp. 367-367
The European Cancer Conference - Lisbon, 21-25 October 2001 - Chairman's introduction
Authors: Senn, HJ
Citation: Hj. Senn, The European Cancer Conference - Lisbon, 21-25 October 2001 - Chairman's introduction, EUR J CANC, 37, 2001, pp. S259-S260
Optimal comprehensive symptom control: an overall strategy
Authors: Senn, HJ
Citation: Hj. Senn, Optimal comprehensive symptom control: an overall strategy, EUR J CANC, 37, 2001, pp. S261-S264
Meeting highlights: International consensus panel on the treatment of primary breast cancer
Authors: Goldhirsch, A Glick, JH Gelber, RD Coates, AS Senn, HJ
Citation: A. Goldhirsch et al., Meeting highlights: International consensus panel on the treatment of primary breast cancer, J CL ONCOL, 19(18), 2001, pp. 3817-3827
Special issue - Tumour prevention and genetics - Introduction
Authors: Senn, HJ Canellos, GP
Citation: Hj. Senn et Gp. Canellos, Special issue - Tumour prevention and genetics - Introduction, EUR J CANC, 36(10), 2000, pp. 1187-1188
Message from the editor-in-chief
Authors: Senn, HJ
Citation: Hj. Senn, Message from the editor-in-chief, EUR J CANC, 36(1), 2000, pp. 6-6
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII
Authors: Crivellari, D Bonetti, M Castiglione-Gertsch, M Gelber, RD Rudenstam, CM Thurlimann, B Price, KN Coates, AS Hurny, C Bernhard, J Lindtner, J Collins, J Senn, HJ Cavalli, F Forbes, J Gudgeon, A Simoncini, E Cortes-Funes, H Veronesi, A Fey, M Goldhirsch, A
Citation: D. Crivellari et al., Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII, J CL ONCOL, 18(7), 2000, pp. 1412-1422
Identifying breast cancer patients at high risk for bone metastases
Authors: Colleoni, M O'Neill, A Goldhirsch, A Gelber, RD Bonetti, M Thurlimann, B Price, KN Castiglione-Gertsch, M Coates, AS Lindtner, J Collins, J Senn, HJ Cavalli, F Forbes, J Gudgeon, A Simoncini, E Cortes-Funes, H Veronesi, A Fey, M Rudenstam, CM
Citation: M. Colleoni et al., Identifying breast cancer patients at high risk for bone metastases, J CL ONCOL, 18(23), 2000, pp. 3925-3935
Intensive course: Mamma carcinoma - Diagnostics and concepts of therapy
Authors: Possinger, K Schlag, PM Senn, HJ
Citation: K. Possinger et al., Intensive course: Mamma carcinoma - Diagnostics and concepts of therapy, ONKOLOGIE, 23(3), 2000, pp. 275-277
Special issue: Millennium Reviews 1999/2000 - Introduction
Authors: Senn, HJ Hart, I Pritchard, J Cannell, E
Citation: Hj. Senn et al., Special issue: Millennium Reviews 1999/2000 - Introduction, EUR J CANC, 35(14), 1999, pp. 1869-1869
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Authors: Sabbioni, MEE Castiglione, M Hurny, C Siegrist, HP Bacchi, M Bernhard, J Thurlimann, B Bonnefoi, H Perey, L Goldhirsch, A Senn, HJ
Citation: Mee. Sabbioni et al., Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients, SUPP CARE C, 7(3), 1999, pp. 149-153
How about trying even harder ...?
Authors: Senn, HJ
Citation: Hj. Senn, How about trying even harder ...?, SUPP CARE C, 7(2), 1999, pp. 59-59
Pamidronate treatment in patients with malignant osteolytic bone disease and pain - A prospective randomized double-blind trial
Authors: Koeberle, D Bacchus, L Thuerlimann, B Senn, HJ
Citation: D. Koeberle et al., Pamidronate treatment in patients with malignant osteolytic bone disease and pain - A prospective randomized double-blind trial, SUPP CARE C, 7(1), 1999, pp. 21-27
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
Authors: Nabholtz, JM Senn, HJ Bezwoda, WR Melnychuk, D Deschenes, L Douma, J Vandenberg, TA Rapoport, B Rosso, R Trillet-Lenoir, V Drbal, J Molino, A Nortier, JWR Richel, DJ Nagykalnai, T Siedlecki, P Wilking, N Genot, JY Hupperets, PSGJ Pannuti, F Skarlos, D Tomiak, EM Murawsky, M Alakl, M Riva, A Aapro, M
Citation: Jm. Nabholtz et al., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy, J CL ONCOL, 17(5), 1999, pp. 1413-1424
Approaching integrated clinical prevention in oncology, the new center fortumor diagnostics and prevention in St. Gallen
Authors: Senn, HJ Glaus, A Bolliger, B Lampert, VD Richter, R
Citation: Hj. Senn et al., Approaching integrated clinical prevention in oncology, the new center fortumor diagnostics and prevention in St. Gallen, ONKOLOGIE, 22(4), 1999, pp. 327-332
Diagnostic and prognostic value of biochemical markers in malignant bone disease: A prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Authors: Engler, H Koeberle, D Thuerlimann, B Senn, HJ Riesen, WF
Citation: H. Engler et al., Diagnostic and prognostic value of biochemical markers in malignant bone disease: A prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease, CLIN CH L M, 36(11), 1998, pp. 879-885
Risultati: 1-17 |